Attorney for Actos Patients Encourages Users to Consult Their Physicians About Alternative Drugs

Share Article

Phoenix Attorney Jonathan O’Steen is encouraging all users of the type 2 diabetes drug Actos (pioglitazone) to consult their physicians about the advisability of switching to other effective drugs that do not pose the serious risks that have been associated with Actos. O’Steen’s law firm, O’Steen & Harrison, represents patients who have been diagnosed with bladder cancer and previously had taken Actos.

phoenix arizona injury lawyer

Jonathan V. O'Steen

Other drugs are available for the treatment of type 2 diabetes which do not pose the same risks as Actos.

Phoenix Attorney Jonathan O’Steen is encouraging all users of the type 2 diabetes drug Actos (pioglitazone) to consult their physicians about the advisability of switching to other effective drugs that do not pose the serious risks that have been associated with Actos. O’Steen’s law firm, O’Steen & Harrison, represents patients who have been diagnosed with bladder cancer and previously had taken Actos.

O’Steen cited interim results of a ten year study undertaken by the drug manufacturer, Takeda Pharmaceutical Company. The health watchdog group Public Citizen reported that although no overall increased risk of bladder cancer was observed in the preliminary data, patients who had the longest exposure to Actos, and those with the highest cumulative use were calculated by the federal Food and Drug Administration (FDA) to have an increased risk of bladder cancer. In addition, Bloomberg News reported that a recent epidemiological study in France has resulted in suspension of Actos use in that country as well as Germany.

The European Medicines Agency, based in London, also is examining data regarding potential cancer risks associated with Actos.

O’Steen believes that all Actos patients should consult their physicians about the advisability of alternative treatments. “Other drugs are available for the treatment of type 2 diabetes which do not pose the same risks as Actos. A conversation with your physician about options would be prudent,” O’Steen concluded.

Patients who believe they may have experienced a health related problem with Actos may report their experience to the FDA’s MedWatch Adverse Event Reporting system.

About O’Steen & Harrison, PLC

O’Steen & Harrison, PLC has protected the rights of injured accident victims and their family members since 1974. The firm concentrates on personal injury, medical malpractice and dangerous products with a special emphasis on dangerous drugs and defective medical devices. O’Steen & Harrison is av-rated (the highest rating) by the prestigious Martindale-Hubbell Law Directory. The firm’s attorneys have recovered more than $3 billion dollars for clients. O’Steen & Harrison offers free, confidential consultations to people nationwide who have taken Actos prescription medication. Call toll free 1-800-883-8888 or see our Actos Lawsuit web site.

SOURCES:
Worst Pills Best Pills Newsletter, November 2011
Bloomberg News, June 9, 2011
U.S Food and Drug Administration, FDA Drug Safety Communication: Ongoing Safety Review of Actos (pioglitazone) and Potential Increased Risk of Bladder Cancer After Two Years Exposure, Sept. 17, 2010

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jonathan V. O'Steen